The association between psoriasis and dyslipidaemia: A systematic review

C. Ma, C. T. Harskamp, E. J. Armstrong, A. W. Armstrong

Research output: Contribution to journalArticle

80 Citations (Scopus)

Abstract

Psoriasis may be associated with dyslipidaemia, a known risk factor for cardiovascular disease. This systematic review aims to synthesize evidence for the association between psoriasis and dyslipidaemia. Through a systematic search using MEDLINE, Embase and the Cochrane Central Register, from 1 January 1980 to 1 January 2012, we identified 25 observational studies that met the inclusion criteria. These 25 studies included over 2.4 million participants, among whom265512 were patients with psoriasis.Twenty studies (80%) reported that psoriasis was significantly associated with dyslipidaemia, with odds ratios (ORs) for dyslipidaemia ranging from 1.04 to 5.55 in 238 385 patients with psoriasis, from a population of 2 340 605 participants. Specifically, four studies defining dyslipidaemia as triglyceride levels ≥ 150 mg dL -11 reported significantly increased ORs of 1.20-4.98 for hypertriglyceridaemia in psoriasis. Three studies found that patients with psoriasis presented with significantly increased ORs (1.36-1.77) for highdensity lipoprotein cholesterol levels < 40 mg dL-1, and two studies found hyperlipoproteinaemia to be significantly elevated in patients with psoriasis (ORs 1.55 and 2.09). One cohort study found a significantly higher incidence of hyperlipidaemia among patients with psoriasis (hazard ratio 1.17;95% confidence interval 1.11-1.23). Among studies that assessed the severity of psoriasis, in 2662 patients with mild psoriasis and 810 patients with severe psoriasis, higher odds of dyslipidaemia were seen in patients with severe psoriasis. Five of the 25 studies (20%) in our review did not show any significant relationship between psoriasis and dyslipidaemia. This systematic review found that psoriasis was significantly associated with greater odds and incidence of dyslipidaemia. Greater psoriasis severity appeared to be associated with higher prevalence of dyslipidaemia.

Original languageEnglish (US)
Pages (from-to)486-495
Number of pages10
JournalBritish Journal of Dermatology
Volume168
Issue number3
DOIs
StatePublished - Mar 2013

Fingerprint

Dyslipidemias
Psoriasis
Odds Ratio
Hyperlipoproteinemias
Hypertriglyceridemia
Incidence
Hyperlipidemias
MEDLINE
Observational Studies

ASJC Scopus subject areas

  • Dermatology
  • Medicine(all)

Cite this

Ma, C., Harskamp, C. T., Armstrong, E. J., & Armstrong, A. W. (2013). The association between psoriasis and dyslipidaemia: A systematic review. British Journal of Dermatology, 168(3), 486-495. https://doi.org/10.1111/bjd.12101

The association between psoriasis and dyslipidaemia : A systematic review. / Ma, C.; Harskamp, C. T.; Armstrong, E. J.; Armstrong, A. W.

In: British Journal of Dermatology, Vol. 168, No. 3, 03.2013, p. 486-495.

Research output: Contribution to journalArticle

Ma, C, Harskamp, CT, Armstrong, EJ & Armstrong, AW 2013, 'The association between psoriasis and dyslipidaemia: A systematic review', British Journal of Dermatology, vol. 168, no. 3, pp. 486-495. https://doi.org/10.1111/bjd.12101
Ma, C. ; Harskamp, C. T. ; Armstrong, E. J. ; Armstrong, A. W. / The association between psoriasis and dyslipidaemia : A systematic review. In: British Journal of Dermatology. 2013 ; Vol. 168, No. 3. pp. 486-495.
@article{ff483bab15974c6ab2b46606fe6819d1,
title = "The association between psoriasis and dyslipidaemia: A systematic review",
abstract = "Psoriasis may be associated with dyslipidaemia, a known risk factor for cardiovascular disease. This systematic review aims to synthesize evidence for the association between psoriasis and dyslipidaemia. Through a systematic search using MEDLINE, Embase and the Cochrane Central Register, from 1 January 1980 to 1 January 2012, we identified 25 observational studies that met the inclusion criteria. These 25 studies included over 2.4 million participants, among whom265512 were patients with psoriasis.Twenty studies (80{\%}) reported that psoriasis was significantly associated with dyslipidaemia, with odds ratios (ORs) for dyslipidaemia ranging from 1.04 to 5.55 in 238 385 patients with psoriasis, from a population of 2 340 605 participants. Specifically, four studies defining dyslipidaemia as triglyceride levels ≥ 150 mg dL -11 reported significantly increased ORs of 1.20-4.98 for hypertriglyceridaemia in psoriasis. Three studies found that patients with psoriasis presented with significantly increased ORs (1.36-1.77) for highdensity lipoprotein cholesterol levels < 40 mg dL-1, and two studies found hyperlipoproteinaemia to be significantly elevated in patients with psoriasis (ORs 1.55 and 2.09). One cohort study found a significantly higher incidence of hyperlipidaemia among patients with psoriasis (hazard ratio 1.17;95{\%} confidence interval 1.11-1.23). Among studies that assessed the severity of psoriasis, in 2662 patients with mild psoriasis and 810 patients with severe psoriasis, higher odds of dyslipidaemia were seen in patients with severe psoriasis. Five of the 25 studies (20{\%}) in our review did not show any significant relationship between psoriasis and dyslipidaemia. This systematic review found that psoriasis was significantly associated with greater odds and incidence of dyslipidaemia. Greater psoriasis severity appeared to be associated with higher prevalence of dyslipidaemia.",
author = "C. Ma and Harskamp, {C. T.} and Armstrong, {E. J.} and Armstrong, {A. W.}",
year = "2013",
month = "3",
doi = "10.1111/bjd.12101",
language = "English (US)",
volume = "168",
pages = "486--495",
journal = "British Journal of Dermatology",
issn = "0007-0963",
publisher = "Wiley-Blackwell",
number = "3",

}

TY - JOUR

T1 - The association between psoriasis and dyslipidaemia

T2 - A systematic review

AU - Ma, C.

AU - Harskamp, C. T.

AU - Armstrong, E. J.

AU - Armstrong, A. W.

PY - 2013/3

Y1 - 2013/3

N2 - Psoriasis may be associated with dyslipidaemia, a known risk factor for cardiovascular disease. This systematic review aims to synthesize evidence for the association between psoriasis and dyslipidaemia. Through a systematic search using MEDLINE, Embase and the Cochrane Central Register, from 1 January 1980 to 1 January 2012, we identified 25 observational studies that met the inclusion criteria. These 25 studies included over 2.4 million participants, among whom265512 were patients with psoriasis.Twenty studies (80%) reported that psoriasis was significantly associated with dyslipidaemia, with odds ratios (ORs) for dyslipidaemia ranging from 1.04 to 5.55 in 238 385 patients with psoriasis, from a population of 2 340 605 participants. Specifically, four studies defining dyslipidaemia as triglyceride levels ≥ 150 mg dL -11 reported significantly increased ORs of 1.20-4.98 for hypertriglyceridaemia in psoriasis. Three studies found that patients with psoriasis presented with significantly increased ORs (1.36-1.77) for highdensity lipoprotein cholesterol levels < 40 mg dL-1, and two studies found hyperlipoproteinaemia to be significantly elevated in patients with psoriasis (ORs 1.55 and 2.09). One cohort study found a significantly higher incidence of hyperlipidaemia among patients with psoriasis (hazard ratio 1.17;95% confidence interval 1.11-1.23). Among studies that assessed the severity of psoriasis, in 2662 patients with mild psoriasis and 810 patients with severe psoriasis, higher odds of dyslipidaemia were seen in patients with severe psoriasis. Five of the 25 studies (20%) in our review did not show any significant relationship between psoriasis and dyslipidaemia. This systematic review found that psoriasis was significantly associated with greater odds and incidence of dyslipidaemia. Greater psoriasis severity appeared to be associated with higher prevalence of dyslipidaemia.

AB - Psoriasis may be associated with dyslipidaemia, a known risk factor for cardiovascular disease. This systematic review aims to synthesize evidence for the association between psoriasis and dyslipidaemia. Through a systematic search using MEDLINE, Embase and the Cochrane Central Register, from 1 January 1980 to 1 January 2012, we identified 25 observational studies that met the inclusion criteria. These 25 studies included over 2.4 million participants, among whom265512 were patients with psoriasis.Twenty studies (80%) reported that psoriasis was significantly associated with dyslipidaemia, with odds ratios (ORs) for dyslipidaemia ranging from 1.04 to 5.55 in 238 385 patients with psoriasis, from a population of 2 340 605 participants. Specifically, four studies defining dyslipidaemia as triglyceride levels ≥ 150 mg dL -11 reported significantly increased ORs of 1.20-4.98 for hypertriglyceridaemia in psoriasis. Three studies found that patients with psoriasis presented with significantly increased ORs (1.36-1.77) for highdensity lipoprotein cholesterol levels < 40 mg dL-1, and two studies found hyperlipoproteinaemia to be significantly elevated in patients with psoriasis (ORs 1.55 and 2.09). One cohort study found a significantly higher incidence of hyperlipidaemia among patients with psoriasis (hazard ratio 1.17;95% confidence interval 1.11-1.23). Among studies that assessed the severity of psoriasis, in 2662 patients with mild psoriasis and 810 patients with severe psoriasis, higher odds of dyslipidaemia were seen in patients with severe psoriasis. Five of the 25 studies (20%) in our review did not show any significant relationship between psoriasis and dyslipidaemia. This systematic review found that psoriasis was significantly associated with greater odds and incidence of dyslipidaemia. Greater psoriasis severity appeared to be associated with higher prevalence of dyslipidaemia.

UR - http://www.scopus.com/inward/record.url?scp=84882248311&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=84882248311&partnerID=8YFLogxK

U2 - 10.1111/bjd.12101

DO - 10.1111/bjd.12101

M3 - Article

C2 - 23106411

AN - SCOPUS:84882248311

VL - 168

SP - 486

EP - 495

JO - British Journal of Dermatology

JF - British Journal of Dermatology

SN - 0007-0963

IS - 3

ER -